85. 特発性間質性肺炎 Idiopathic interstitial pneumonia Clinical trials / Disease details
臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05722964 (ClinicalTrials.gov) | February 2023 | 11/1/2023 | Study on Intravenous Injection of SHR-1906 in the Treatment of Idiopathic Pulmonary Fibrosis | Efficacy and Safety of Intravenous Infusion of SHR-1906 in Patients With Idiopathic Pulmonary Fibrosis: a Multicenter, Randomized, Double-blind, Parallel Placebo-controlled Phase II Trial | Idiopathic Pulmonary Fibrosis | Drug: SHR-1906;Drug: Placebo | Guangdong Hengrui Pharmaceutical Co., Ltd | NULL | Not yet recruiting | 40 Years | 80 Years | All | 108 | Phase 2 | NULL |
2 | NCT04986540 (ClinicalTrials.gov) | August 10, 2021 | 27/7/2021 | A Trial of SHR - 1906 in Healthy Subjects | A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single IV Infusion of SHR-1906 in Healthy Subjects | Idiopathic Pulmonary Fibrosis | Drug: SHR-1906;Placebo | Guangdong Hengrui Pharmaceutical Co., Ltd | NULL | Completed | 18 Years | 55 Years | All | 72 | Phase 1 | China |